Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
enapotamab vedotin
- Development stage
- Discontinued
- Lead developer
- Genmab
- Modality
- Small Molecules, Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
Enapotamab vedotin is an investigational antibody-drug conjugate (ADC) developed by Genmab for the treatment of solid tumors. It consists of a fully human IgG1 monoclonal antibody targeting AXL, a receptor tyrosine kinase overexpressed in various hematologic and solid malignancies, conjugated via a linker to the cytotoxic agent monomethyl auristatin E (MMAE). The drug is designed to selectively deliver MMAE to AXL-expressing tumor cells, where it inhibits tubulin polymerization and induces apoptosis. Enapotamab vedotin was evaluated in phase 1/2 clinical trials for multiple advanced solid tumors but its development was discontinued after expansion cohort data did not meet proof-of-concept criteria[2][3][4][5].
- Other names
- enapotamab vedotinHuMax-AXLImmunoglobulin g1, anti-(human growth factor receptor axl)(human humax-axl .gamma.1-chain), disulfide with human humax-axl .kappa.-chain, dimer tetrakis(thioether) with vedotin
02
Targets
TUBB (Tubulin (alpha and beta subunits))AXL (AXL receptor tyrosine kinase)
Beyond the preview
Go deeper on enapotamab vedotin.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on enapotamab vedotin.